Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 24 of 37, showing 5 Applications out of 181 total, starting on record 116, ending on 120

# Protocol No Study Title Investigator(s) & Site(s)

116.

ECCT/20/07/03   STAND
    A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND)   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. CREATES Strathmore University (Nairobi City county)
2. Getrudes Childrens Hospital (Nairobi City county)
3. International Cancer Institute (Elgeyo/Marakwet county)
 
View

117.

ECCT/20/06/04   ANTICOV (01 COV)
    An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild /moderate cases of COVID-19   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Mbagathi Infectious Disease Hospital (Nairobi City county)
2. Kenyatta University Teaching, Referral and Research Hospital (Nairobi City county)
 
View

118.

ECCT/20/06/02   EMPACTA Covid19 Study
    A RANDOMIZED, DOUBLE-BLIND, Placebo-Controlled, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOCILIZUMAB IN HOSPITALIZED PATIENTS WITH COVID‑19 PNEUMONIA   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
AgaKhan University Hospital Nairobi
 
View

119.

ECCT/20/05/02   COPCOV
    Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)   
Principal Investigator(s)
1. Anthony Oliwa Etyang
Site(s) in Kenya
1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county)
2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county)
 
View

120.

ECCT/20/04/03   518 & 525-SHAN6™
    Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants.    Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age   
Principal Investigator(s)
1. Bernhards Ogutu
2. Godfrey Allan Otieno
3. Videlis Nduba
4. Lucy Chepkurui Koech
5. samuel Gurrion Ouma
6. Janet Oyieko
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
3. KEMRI Kondele Children’s Hospital (Kisumu county)
4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county)
5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county)
6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county)
7. CRDR_Siaya Annex(Back-up site) (Siaya county)
 
View